Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
MWN-AI** Summary
On February 12, 2026, Coherus Oncology, Inc. (NASDAQ: CHRS) announced the pricing of an underwritten public offering of 28,600,000 shares of its common stock at a price of $1.75 per share. This offering, which is entirely made up of shares sold by the Company, is expected to generate approximately $50.1 million in gross proceeds before expenses. The offering is set to close around February 17, 2026, pending customary conditions.
Coherus plans to utilize the net proceeds from this offering to further the commercialization of LOQTORZI® (toripalimab-tpzi), continue the clinical development of other product candidates, and support overall working capital and corporate purposes. LOQTORZI is Coherus' approved next-generation PD-1 inhibitor targeted at treating nasopharyngeal carcinoma among other indications.
In addition to the 28.6 million shares, the underwriters have a 30-day option to purchase up to an additional 4,290,000 shares at the offering price, ensuring flexibility and potential for increased capital raise. The offering will be conducted under an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission (SEC) on November 13, 2025.
Key participants in the underwriting process include TD Cowen, Guggenheim Securities, and Oppenheimer & Co., acting as joint bookrunners. For prospective investors, prospectus supplements and related documents will be accessible through the SEC's website.
Coherus Oncology operates in the oncology sector with a pipeline that addresses multiple cancer types, including prostate and colorectal cancers. The Company aims to enhance treatment outcomes and advance its developmental pipeline, underscoring its commitment to innovative cancer care solutions.
MWN-AI** Analysis
Coherus Oncology, Inc. (NASDAQ: CHRS) has announced a public offering of 28.6 million shares at a price of $1.75 per share, which is projected to raise approximately $50.1 million in gross proceeds. This capital raise is strategically aimed at bolstering the commercialization efforts for LOQTORZI® (toripalimab-tpzi) and advancing its developmental pipeline, which includes promising candidates targeting a range of cancers.
Investors should analyze the implications of this offering. The dilution of current shareholders due to increased share count could have a short-term bearish impact on the stock price. However, the net proceeds will be pivotal for the company’s growth strategy, particularly in expanding the market for LOQTORZI, which is pivotal in treating recurrent/metastatic nasopharyngeal carcinoma.
Coherus' focus on its innovative oncology pipeline and targeted clinical studies lends potential for long-term revenue growth. Key products such as Tagmokitug and Casdozokitug are in pivotal phases of clinical trials, which, if successful, could lead to significant commercial opportunities.
Market sentiment surrounding biotechnology stocks is often influenced by the progress of clinical trials and regulatory approvals. Investors should remain vigilant of upcoming data releases regarding the product candidates, as positive results could significantly uplift stock valuations. Conversely, setbacks in clinical trials pose substantial risks, given the inherent volatility in the biotech sector.
Given these dynamics, Coherus may present a speculative opportunity for investors looking for exposure to the oncology sector, especially for those with a high-risk tolerance. It’s advisable to monitor the stock closely post-offering, as price adjustments in response to dilution and the operational use of the raised capital will unfold over the coming months. Adding Coherus to a diversified portfolio could provide both risk and rewarding potential, considering ongoing innovations and strategic positioning in a competitive market.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the pricing of an underwritten public offering of 28,600,000 shares of the Company’s common stock (the “Offering”). The shares of common stock are being sold at a public offering price of $1.75 per share, before underwriting discounts and commissions. All of the shares in the Offering are being sold by the Company. The gross proceeds to Coherus from the Offering are expected to be approximately $50.1 million, before deducting underwriting discounts and commissions and other offering expenses. The Company has granted the underwriters of the Offering a 30-day option to purchase up to an additional 4,290,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. The Offering is expected to close on or about February 17, 2026, subject to the satisfaction of customary closing conditions.
Coherus intends to use the net proceeds from the Offering to support the ongoing commercialization of LOQTORZI® (toripalimab-tpzi), to continue clinical development of its product candidates, and for working capital and other general corporate purposes.
TD Cowen, Guggenheim Securities, and Oppenheimer & Co. are acting as the joint bookrunners for the Offering.
The securities described above are being offered by Coherus pursuant to an effective shelf registration statement on Form S-3 (File No. 333-291520) that was previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 13, 2025. The Offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A prospectus supplement and accompanying prospectus relating to and describing the terms of the Offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to these securities may be obtained, when available, by request from: TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or Oppenheimer & Co. Inc. Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Coherus Oncology, Inc.
Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, prostate, head & neck, colorectal and other cancers. The Company’s strategy is to grow sales of LOQTORZI in R/M nasopharyngeal carcinoma and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as through its partners.
Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, and esophageal cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.
LOQTORZI® is a registered trademark of Coherus Oncology, Inc.
©2026 Coherus Oncology, Inc. All rights reserved.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including, without limitation, statements regarding the completion of the Offering, the expected gross proceeds of the Offering, the anticipated use of proceeds from the Offering and the potential exercise by the underwriters of an option to purchase additional shares, are forward-looking statements reflecting the current beliefs and expectations of Coherus’ management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent Coherus’ current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are market conditions, including market interest rates, tariffs, the trading price and volatility of Coherus’ common stock, the satisfaction of closing conditions related to the Offering, and risks relating to Coherus’ business, including those identified in the “Risk Factors” section of Coherus’ Annual Report on Form 10-K for the year ended December 31, 2024, in its subsequent Quarterly Reports on Form 10-Q and other filings with the SEC, as well as the prospectus supplement and accompanying prospectus relating to the Offering. The forward-looking statements included in this press release speak only as of the date of this press release, and Coherus does not undertake to update the statements included in this press release for subsequent developments, except as may be required by law.
Coherus Oncology Contact Information:
For Investors:
Carrie Graham
VP, Investor Relations & Advocacy
IR@coherus.com
FAQ**
How does the recent public offering of Coherus BioSciences Inc. (NASDAQ: CHRS) impact its ability to advance the commercialization of LOQTORZI® and further develop its oncology pipeline in the competitive market?
What specific strategies does Coherus BioSciences Inc. (CHRS) plan to implement with the estimated $50.1 million raised from the public offering to enhance its position in the oncology market?
Given the ongoing clinical trials, how will Coherus BioSciences Inc. (NASDAQ: CHRS) allocate funds from the public offering among its product candidates, specifically Tagmokitug and Casdozokitug?
What risks and uncertainties should investors consider regarding Coherus BioSciences Inc. (CHRS) following the announcement of this public offering, particularly in relation to market conditions and the Company’s business operations?
**MWN-AI FAQ is based on asking OpenAI questions about Coherus BioSciences Inc. (NASDAQ: CHRS).
NASDAQ: CHRS
CHRS Trading
0.0% G/L:
$1.595 Last:
428,890 Volume:
$1.57 Open:
